<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Judd W Moul, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W Robert Lee, MD, MS, MEd</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prostate-specific antigen (PSA) is a sensitive and specific serum marker for prostate tissue. Serial measurements are routinely obtained to detect early disease recurrence in males who have received definitive treatment for localized disease.</p><p>The role of definitive salvage therapy after initial radiation therapy (RT; external beam or brachytherapy) is reviewed here. Other aspects of patient management for males with a rising serum PSA following initial RT are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6950.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6929.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6952.html" rel="external">"Rising or persistently elevated serum PSA following radical prostatectomy for prostate cancer: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6933.html" rel="external">"Role of systemic therapy in patients with a biochemical recurrence after treatment for localized prostate cancer"</a>.)</p><p></p><p class="headingAnchor" id="H449015788"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>Monitoring PSA after treatment of localized prostate cancer can lead to the identification of males with a PSA-only (biochemical) recurrence. In this situation, increases in serum PSA over the baseline after initial treatment are not accompanied by symptoms or signs of locally recurrent or metastatic disease. Many of these males are relatively young and otherwise healthy. For males in whom there is a significant likelihood that disease is confined to the prostate gland, salvage therapy may result in prolonged disease-free survival  (<a class="graphic graphic_algorithm graphicRef100471" href="/d/graphic/100471.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a confirmed rise in serum PSA following prior definitive RT, careful evaluation is required to rule out the possibility of distant metastases. The staging evaluation may include computed tomography (CT) of the abdomen and pelvis, bone scan, and/or positron emission tomography (PET) scan using one of the more sensitive prostate cancer-specific radiotracers (eg, F-18 fluciclovine [Axumin]), or prostate-specific membrane antigen (PSMA) PET/CT, where available. (See  <a class="medical medical_review" href="/d/html/6929.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation", section on 'Accuracy of individual tests and procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the absence of metastatic disease or other contraindications to local salvage therapy, many clinicians, including the authors and editors associated with this review, perform multiparametric prostate magnetic resonance imaging (MRI) to guide a confirmatory biopsy if salvage surgery/cryotherapy/brachytherapy/or high-intensity focused ultrasound is being considered. The finding of seminal vesicle invasion or extraprostatic extension on multiparametric MRI identifies males who are unlikely to achieve long-term disease control from salvage radical prostatectomy. (See  <a class="medical medical_review" href="/d/html/6929.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation", section on 'Males previously treated with radiation therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a positive prostate biopsy, without evidence of disseminated disease, and who are candidates for salvage therapy, treatment options include radical prostatectomy, cryotherapy, and brachytherapy. (See <a class="local">'Radical prostatectomy'</a> below and <a class="local">'Cryotherapy'</a> below and <a class="local">'Brachytherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients without disseminated disease who have received definitive RT and are not candidates for salvage therapy, systemic therapy may be indicated. (See  <a class="medical medical_review" href="/d/html/6933.html" rel="external">"Role of systemic therapy in patients with a biochemical recurrence after treatment for localized prostate cancer"</a>.)</p><p></p><p class="headingAnchor" id="H81458203"><span class="h1">DEFINITION OF BIOCHEMICAL FAILURE</span><span class="headingEndMark"> — </span>The interpretation of changes in serum PSA after RT can be difficult since some normal prostatic glandular tissue is present. Thus, serum PSA levels are unlikely to fall to undetectable levels following a course of RT.</p><p>The most widely accepted definition is the so-called Phoenix criteria, established by the American Society for Radiation Oncology (ASTRO) [<a href="#rid1">1</a>]. According to this definition, a PSA rise of ≥2 ng/mL above the nadir PSA is considered a biochemical failure in a patient who was previously treated with definitive RT, with or without androgen deprivation therapy (ADT). Although an increase of 2 ng/mL or more is defined as a biochemical relapse, repeat confirmation is generally carried out to rule out a PSA bounce. (See  <a class="medical medical_review" href="/d/html/6950.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification", section on 'After radiation therapy'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATIENT SELECTION FOR LOCAL SALVAGE THERAPY</span><span class="headingEndMark"> — </span>Formal criteria have not been established to determine which males are candidates for local salvage therapy following a PSA-only recurrence. The decision of whether or not to proceed to local salvage therapy requires consideration of the likelihood that the disease is locally confined in combination with an assessment of the patient's age and overall health. (See  <a class="medical medical_review" href="/d/html/6929.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation"</a>.)</p><p>Clinical and pathologic parameters at the time of original diagnosis, as well as subsequent events, are helpful in predicting those males who are most likely to benefit from aggressive salvage therapy and least likely to develop distant metastases and die from their disease.</p><p class="bulletIndent1"><span class="glyph">●</span>Males who were classified as high or very high risk  (<a class="graphic graphic_table graphicRef118962" href="/d/graphic/118962.html" rel="external">table 1</a>) at their original presentation are at increased risk for developing distant disease following initial therapy and are less likely to benefit from local salvage therapy. In particular, this includes males who originally had a histologic grade group of 4 or 5 (Gleason score ≥8), a clinical tumor stage ≥T2c, or a serum PSA level &gt;20 ng/mL [<a href="#rid2">2,3</a>]. This corresponds to prognostic stage groups II and III in the most recent tumor, node, metastasis (TNM) staging system from the American Joint Committee on Cancer (AJCC)  (<a class="graphic graphic_table graphicRef110728" href="/d/graphic/110728.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef110729" href="/d/graphic/110729.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A shorter interval from treatment to biochemical failure was significantly associated with an increase in prostate cancer-specific mortality in a study of 1722 males treated with RT for prostate cancer [<a href="#rid4">4</a>]. The five-year prostate cancer-specific mortality was significantly higher in those with an interval to biochemical failure &lt;18 months compared with an interval &gt;18 months (26 versus 9 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A short PSA doubling time following initial therapy is correlated with an increased risk of subsequent distant metastases. As an example, in one study, a PSA doubling time &lt;8 months was associated with a 54 percent risk of distant metastases at seven years, and in another report, a PSA doubling time &lt;3 months correlated with a 49 percent risk of distant metastases at three years [<a href="#rid5">5,6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A serum PSA &gt;10 ng/mL at the time of evaluation for salvage therapy correlates with a poorer outcome following therapy for a PSA-only recurrence [<a href="#rid7">7,8</a>].</p><p></p><p>Although long-term outcomes are better with early treatment for a PSA-only recurrence, these results may reflect the natural history of the disease and do not necessarily reflect a benefit from therapy. Males with a PSA-only relapse and relatively low PSA levels (particularly those with a low Gleason score, clinical stage T1 or T2 tumors, a long PSA doubling time, and a long interval to PSA recurrence) are more likely to have a prolonged disease course even without treatment. The lack of randomized trials comparing surgery or another form of local therapy versus observation makes it difficult to know whether these males would have remained free of clinical metastases even without salvage therapy. (See  <a class="medical medical_review" href="/d/html/6950.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification", section on 'Risk of metastases or death'</a>.)</p><p class="headingAnchor" id="H2852899376"><span class="h2">Need for biopsy confirmation</span><span class="headingEndMark"> — </span>Local salvage therapy is associated with the risk of clinically significant toxicity and should not be undertaken unless there is biopsy confirmation of a local recurrence. In the era of improved multiparametric MRI of the prostate, it might be tempting to offer salvage therapy based on MRI alone, but this is not recommended and biopsy confirmation of a local recurrence remains indicated.</p><p class="headingAnchor" id="H2987109"><span class="h1">OPTIONS FOR SALVAGE THERAPY</span><span class="headingEndMark"> — </span>There is no consensus on the optimal approach to salvage local therapy and clinical practice is variable. The available options are radical prostatectomy, brachytherapy, and cryotherapy. There are no randomized trials that compare different therapeutic options with each other or with observation in this setting. A systematic review of the literature found the five-year recurrence-free survival rates to be similar with different modalities, although there are differences in the toxicity profiles [<a href="#rid9">9</a>]. The choice of a specific intervention is often dependent on available experience and expertise. Even though high-intensity focused ultrasound (HIFU) is approved by the US Food and Drug Administration (FDA) for destruction of prostate tissue, it is not approved explicitly for the treatment of prostate cancer, and we do not use HIFU to treat locally recurrent prostate cancer. (See  <a class="medical medical_review" href="/d/html/6930.html" rel="external">"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer", section on 'High-intensity focused ultrasound'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Radical prostatectomy</span><span class="headingEndMark"> — </span>Salvage prostatectomy provides prolonged disease control in many patients. In the pre-PSA era, surgery was not widely used because of concerns about operative morbidity and the frequent development of disseminated metastases. More contemporary experience utilizing better patient selection criteria and improved operative techniques has made radical prostatectomy an important option for appropriately selected patients, particularly those with a life expectancy of 10 to 15 years or more [<a href="#rid10">10</a>]. Although most of the literature is based on open radical prostatectomy, minimally invasive techniques appear to be an option for experienced surgeons [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/6944.html" rel="external">"Radical prostatectomy for localized prostate cancer"</a>.)</p><p class="headingAnchor" id="H4"><span class="h3">Preoperative evaluation</span><span class="headingEndMark"> — </span>Prior to surgery, appropriate studies should be conducted to rule out disseminated disease and to provide a tissue confirmation of the diagnosis of a recurrence in the prostate. In males who are candidates for radical prostatectomy, cystoscopic examination is helpful to rule out bladder neck involvement or urethral strictures. (See  <a class="medical medical_review" href="/d/html/6929.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Disease control</span><span class="headingEndMark"> — </span>The most extensive contemporary evidence on the efficacy of salvage radical prostatectomy comes from a multi-institutional series of 404 males with recurrent prostate cancer following RT [<a href="#rid12">12</a>]. With a median follow-up of 4.4 years, the 10-year biochemical relapse-free, metastasis-free, and cancer-specific survival rates following salvage radical prostatectomy were 48, 83, and 92 percent, respectively. Factors associated with an improved prognosis included a lower serum PSA prior to salvage radical prostatectomy and a lower Gleason score in the post-RT biopsy.</p><p>Data on the use of minimally invasive techniques for salvage radical prostatectomy are more limited [<a href="#rid13">13</a>]. Although the results appear similar, more experience and longer follow-up are required [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Complications</span><span class="headingEndMark"> — </span>Radical prostatectomy is technically more challenging and is associated with an increased risk of significant complications in patients who have had prior RT compared with those who have not had prior RT [<a href="#rid15">15</a>]. Older series of patients treated with salvage prostatectomy reported major complications in one-third to one-half of all males [<a href="#rid16">16-18</a>]. These included rectal injury, bladder neck contractures, hemorrhage, ureteral injury, vesicorectal or vesicoperineal fistulas, venous thromboembolism, and chronic urinary incontinence.</p><p>These series included many patients who had undergone staging pelvic lymph node dissection and/or open radioactive seed implantation. The degree of fibrosis after modern conformal external beam RT or transperineal brachytherapy is much less, permitting the majority of males to undergo a salvage operation that is similar to the standard non-salvage prostatectomy [<a href="#rid19">19</a>]. In three large contemporary series, the rate of early perioperative complications ranged from 13 to 27 percent [<a href="#rid20">20-22</a>]. A summary of the acute and late complications in three salvage radical prostatectomy series is presented in the table  (<a class="graphic graphic_table graphicRef59796" href="/d/graphic/59796.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/6944.html" rel="external">"Radical prostatectomy for localized prostate cancer", section on 'Functional outcomes'</a>.)</p><p>However, late rates of urinary incontinence (30 to 70 percent) and anastomotic stricture (17 to 32 percent) do not appear to have improved substantially despite better patient selection, less pelvic fibrosis, and better surgical technique [<a href="#rid15">15,22,23</a>]. These rates are substantially higher than those observed after radical prostatectomy as initial therapy. This may reflect the persistence of radiation-induced sphincter dysfunction. When the assessment is based on patient-reported data, even higher rates of incontinence have been reported [<a href="#rid19">19</a>]. The incidence of incontinence may also be biased by the use of an artificial urinary sphincter in some patients.</p><p>Erectile dysfunction is generally a consequence of salvage prostatectomy. However, nerve preservation is sometimes feasible, and occasional males with adequate preoperative erectile function may recover potency after bilateral nerve-sparing salvage prostatectomy. In one retrospective series, 45 percent of males who were potent preoperatively maintained potency [<a href="#rid19">19</a>], and males were more likely to recover erectile function if they had bilateral preservation of the neurovascular bundles [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Perioperative androgen deprivation therapy</span><span class="headingEndMark"> — </span>There are no randomized trials that address the role of adjuvant or neoadjuvant androgen deprivation therapy (ADT) in males undergoing salvage prostatectomy. Small retrospective series have reported on the use of perioperative ADT in this setting, but these reports do not provide reliable information on the efficacy of these approaches [<a href="#rid8">8,18,25</a>]. Our approach is to perform salvage prostatectomy and monitor PSA postoperatively without adjuvant or neoadjuvant ADT.</p><p class="headingAnchor" id="H8"><span class="h2">Cryotherapy</span><span class="headingEndMark"> — </span>For males with locally recurrent disease, cryoablation is less invasive than salvage prostatectomy, and it seems to have fewer side effects (particularly incontinence and rectal injury) compared with salvage radical prostatectomy. This approach might be preferred over salvage radical prostatectomy for males over age 70 who have an isolated local recurrence after EBRT, and for any patient who is not willing to accept a 10 to 25 percent risk of long-term incontinence or a 1 to 5 percent risk of rectal injury after salvage radical prostatectomy.</p><p>The rationale and techniques for prostate cryotherapy, as well as its use for the initial treatment of prostate cancer, are discussed separately. (See  <a class="medical medical_review" href="/d/html/6930.html" rel="external">"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer"</a>.)</p><p class="headingAnchor" id="H85229518"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of cryoablation as a salvage therapy following RT has been evaluated only in retrospective series. Many of these reports used older cryotherapy techniques, and their interpretation is further limited by variable definitions of biochemical failure.</p><p>The most extensive data come from an analysis of 328 patients who underwent salvage cryosurgery between 1994 and 2011 [<a href="#rid26">26</a>]. Primary treatment had included external beam RT or brachytherapy in 308 cases (94 percent) and cryotherapy in 20 patients (6 percent). The 5- and 10-year recurrence-free survival rates were 63 and 35 percent, respectively, and the 5- and 10-year disease-specific survival rates were 91 and 79 percent, respectively. Factors associated with a better prognosis included an increasing time interval from original treatment to salvage therapy, a lower serum PSA level at the time of surgery, and a lower PSA nadir after cryotherapy.</p><p>Similar results have been reported in other series [<a href="#rid27">27-29</a>].</p><p class="headingAnchor" id="H85229545"><span class="h3">Complications</span><span class="headingEndMark"> — </span>Patients can experience the same range of complications following salvage cryotherapy as have been observed when cryotherapy is used for the treatment of primary localized prostate cancer. (See  <a class="medical medical_review" href="/d/html/6930.html" rel="external">"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer", section on 'Complications'</a>.)</p><p>However, the complications of salvage cryotherapy appear to be more common and more severe than those of primary cryotherapy. These differences include the full array of potential cryotherapy complications. As with cryoablation for primary therapy of prostate cancer, effective urethral warming is essential to reduce complications and maximize quality of life for males undergoing salvage cryoablation [<a href="#rid30">30</a>].</p><p>In the Cryo On-Line Data (COLD) registry series, urinary incontinence sufficient to require the use of pads was reported in 4 percent of cases [<a href="#rid27">27</a>]. However, the reported rates of incontinence were substantially higher in a study that relied on patient, rather than clinician, reporting [<a href="#rid31">31</a>]. Forty-six males undergoing salvage cryotherapy were asked to complete quality of life forms before and after therapy. Urinary bother was a moderate to big problem 24 months after cryotherapy in 29 percent; 73 percent reported leaking of urine daily or weekly, and 53 percent needed one or more pads daily.</p><p>The net effect is that salvage cryotherapy may not offer quality of life advantages compared with salvage prostatectomy in males with locally recurrent disease following RT [<a href="#rid30">30</a>]. However, the modern argon-based cryotherapy technique seems to have fewer complications than older techniques [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/6930.html" rel="external">"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer", section on 'Technique'</a>.)</p><p class="headingAnchor" id="H85229635"><span class="h3">Cryotherapy versus salvage prostatectomy</span><span class="headingEndMark"> — </span>There are no prospective studies that directly compare cryosurgery with radical prostatectomy or brachytherapy after failure of external beam RT.</p><p>A retrospective study compared 42 males treated with salvage prostatectomy at the Mayo Clinic with 56 patients treated with salvage cryotherapy at MD Anderson Cancer Center. Patients were matched for pretreatment PSA and biopsy Gleason score [<a href="#rid32">32</a>]. Biochemical progression occurred more frequently in patients treated with salvage cryotherapy than in those treated with radical prostatectomy (five-year biochemical relapse-free survival 66 versus 42 percent, based on a criterion of two increases in serum PSA above the nadir). There was no difference in five-year disease-specific survival (96 versus 98 percent). The choice of therapy needs to be individualized, and cryotherapy is appropriate for older patients and those with significant comorbidity.</p><p>Cryotherapy can freeze and destroy tissue beyond the confines of the prostate gland, and this may be an advantage compared with radical prostatectomy in some patients. Guidelines from the American Urological Association (AUA) support cryotherapy as an option in this setting [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Brachytherapy</span><span class="headingEndMark"> — </span>Brachytherapy is another option for salvage treatment in males with a biochemical recurrence following initial management with external beam RT [<a href="#rid34">34</a>]. Brachytherapy is typically given using a low-dose-rate methodology with iodine-125 (I-125) or palladium-103 (Pd-103) [<a href="#rid35">35-40</a>], but it can also be given using a high-dose-rate technique [<a href="#rid41">41-43</a>]. (See  <a class="medical medical_review" href="/d/html/6923.html" rel="external">"Brachytherapy for low-risk or favorable intermediate-risk, clinically localized prostate cancer", section on 'Technique'</a>.)</p><p>There are no randomized trials comparing brachytherapy with other forms of salvage therapy. The following results are available from uncontrolled trials and retrospective analyses:</p><p class="bulletIndent1"><span class="glyph">●</span>In the prospective multicenter phase II RTOG 0526 trial, in which 100 individuals with low/intermediate-risk prostate cancer before EBRT who had a biopsy-proven local recurrence &gt;30 months after RT, a PSA &lt;10 ng/mL, and no evidence of regional/distant disease (as assessed by bone scan and abdominopelvic CT scan) all received transperineal template-guided LDR brachytherapy using either iodine-125 or palladium-123 seeds [<a href="#rid40">40</a>]. Overall, 92 were eligible and received protocol treatment. Concurrent or prior ADT was prescribed for 16 percent at the time of salvage; with minimum five-year follow-up (median 6.7 years), the five-year freedom from biochemical failure rate was 68 percent. At ten years, local failures were rare (5 percent), but 46 percent had biochemical failure. Ten-year overall survival was 70 percent; of the 19 patients who died, five died from their prostate cancer, 10 from other causes, 4 of unknown causes. Treatment-related toxicity was not reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional information, including toxicity information is available from one of the largest retrospective series, which included 108 males with a biopsy-proven local recurrence after external beam RT underwent salvage low-dose-rate brachytherapy [<a href="#rid39">39</a>]. At an average follow-up of 6.3 years, the freedom from biochemical failure rates at 5 and 10 years were 63 and 52 percent, respectively, and rates of prostate cancer-specific survival were 91 and 78 percent, respectively. Grade 3 toxicity occurred in 17 percent of patients, mostly genitourinary (15.7 percent) rather than gastrointestinal (2.8 percent), and the vast majority were late, occurring more than six months following brachytherapy.</p><p></p><p class="headingAnchor" id="H4187307614"><span class="h2">High-intensity focused ultrasound</span><span class="headingEndMark"> — </span>HIFU uses sonic waves to create thermal energy that destroys the target tissue within the prostate. HIFU has been used as salvage therapy for the treatment of biopsy-proven recurrent prostate cancer following RT [<a href="#rid44">44</a>]. Updated guidelines on treatment of prostate cancer from the European Society of Medical Oncology also include HIFU as an option for local salvage therapy after initial RT for localized prostate cancer [<a href="#rid45">45</a>]. However, the risk of significant complications in this setting is higher compared with primary therapy [<a href="#rid46">46</a>]. Given that HIFU lacks robust evidence of efficacy both for primary and savage treatment, and that even though HIFU is approved by the FDA for destruction of prostate tissue, it is not approved explicitly for the treatment of prostate cancer, and we do not use HIFU to treat locally recurrent prostate cancer. (See  <a class="medical medical_review" href="/d/html/6930.html" rel="external">"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer", section on 'High-intensity focused ultrasound'</a>.)</p><p class="headingAnchor" id="H497002740"><span class="h1">SUBSEQUENT BIOCHEMICAL RECURRENCE</span><span class="headingEndMark"> — </span>Serum PSA levels should be monitored after salvage therapy (eg, radical prostatectomy) for a biochemical recurrence following RT. Evidence of a further biochemical recurrence is not uncommon in this situation.</p><p>The primary approach to management of a subsequent biochemical recurrence is androgen deprivation therapy (ADT). The optimal timing for the initiation of ADT in this situation is not clear. (See  <a class="medical medical_review" href="/d/html/6933.html" rel="external">"Role of systemic therapy in patients with a biochemical recurrence after treatment for localized prostate cancer", section on 'ADT monotherapy'</a>.)</p><p class="headingAnchor" id="H4235251440"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117831.html" rel="external">"Society guideline links: Diagnosis and management of prostate cancer"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of biochemical failure</strong> – The routine monitoring of serum prostate-specific antigen (PSA) after treatment of early stage prostate cancer has led to the identification of males with a PSA-only (biochemical) recurrence without symptoms or signs of locally recurrent or disseminated prostate cancer. The most widely accepted definition of biochemical failure following radiation therapy (RT) is the Phoenix criteria. According to this definition, a PSA rise of ≥2 ng/mL above the nadir PSA following definitive RT (external beam or brachytherapy) is considered a biochemical failure. (See <a class="local">'Definition of biochemical failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection for salvage therapy</strong> – Formal criteria have not been established to determine which males are candidates for local salvage therapy following a PSA-only recurrence. The decision of whether or not to proceed to local salvage therapy requires consideration of the likelihood that the disease is locally confined in combination with an assessment of the patient's age and overall health. Tissue confirmation of the localized recurrence should be pursued prior to salvage local therapy. (See  <a class="medical medical_review" href="/d/html/6929.html" rel="external">"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation"</a> and <a class="local">'Patient selection for local salvage therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Options for salvage local therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no consensus on the optimal approach to salvage local therapy and clinical practice is variable. The available options are radical prostatectomy, brachytherapy, and cryotherapy. There are no randomized trials that compare different therapeutic options with each other or with observation in this setting. Five-year recurrence-free survival rates appear to be similar with different modalities, although there are differences in the toxicity profiles. Key factors in choosing the approach include age, comorbidity, patient preferences, and the availability of local experience and expertise. (See <a class="local">'Options for Salvage therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Even though high-intensity focused ultrasound (HIFU) is approved by the US Food and Drug Administration for destruction of prostate tissue, it is not approved explicitly for the treatment of prostate cancer, and we do not use HIFU to treat locally recurrent prostate cancer. (See <a class="local">'High-intensity focused ultrasound'</a> above.)</p><p></p><p class="headingAnchor" id="H2960137862"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965.</a></li><li><a class="nounderline abstract_t">Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007; 110:1417.</a></li><li><a class="nounderline abstract_t">Kishan AU, Chu FI, King CR, et al. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Eur Urol 2020; 77:201.</a></li><li><a class="nounderline abstract_t">Buyyounouski MK, Pickles T, Kestin LL, et al. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 2012; 30:1857.</a></li><li><a class="nounderline abstract_t">Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997; 44:213.</a></li><li><a class="nounderline abstract_t">Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005; 23:826.</a></li><li><a class="nounderline abstract_t">de la Taille A, Hayek O, Benson MC, et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology 2000; 55:79.</a></li><li><a class="nounderline abstract_t">Tiguert R, Rigaud J, Lacombe L, et al. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol 2003; 170:447.</a></li><li><a class="nounderline abstract_t">Valle LF, Lehrer EJ, Markovic D, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol 2021; 80:280.</a></li><li><a class="nounderline abstract_t">Chade DC, Eastham J, Graefen M, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012; 61:961.</a></li><li><a class="nounderline abstract_t">Kaffenberger SD, Keegan KA, Bansal NK, et al. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol 2013; 189:507.</a></li><li><a class="nounderline abstract_t">Chade DC, Shariat SF, Cronin AM, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol 2011; 60:205.</a></li><li><a class="nounderline abstract_t">Rocco B, Cozzi G, Spinelli MG, et al. Current status of salvage robot-assisted laparoscopic prostatectomy for radiorecurrent prostate cancer. Curr Urol Rep 2012; 13:195.</a></li><li><a class="nounderline abstract_t">Punnen S, Cooperberg MR, D'Amico AV, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 2013; 64:905.</a></li><li><a class="nounderline abstract_t">Gotto GT, Yunis LH, Vora K, et al. Impact of prior prostate radiation on complications after radical prostatectomy. J Urol 2010; 184:136.</a></li><li><a class="nounderline abstract_t">Rogers E, Ohori M, Kassabian VS, et al. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995; 153:104.</a></li><li><a class="nounderline abstract_t">Moul JW, Paulson DF. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer 1991; 68:1265.</a></li><li><a class="nounderline abstract_t">Lerner SE, Blute ML, Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995; 154:1103.</a></li><li><a class="nounderline abstract_t">Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004; 172:2239.</a></li><li><a class="nounderline abstract_t">Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005; 173:1156.</a></li><li><a class="nounderline abstract_t">Gheiler EL, Tefilli MV, Tiguert R, et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998; 51:789.</a></li><li><a class="nounderline abstract_t">Bianco FJ Jr, Scardino PT, Stephenson AJ, et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62:448.</a></li><li><a class="nounderline abstract_t">Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005; 23:8198.</a></li><li><a class="nounderline abstract_t">Masterson TA, Stephenson AJ, Scardino PT, Eastham JA. Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Urology 2005; 66:623.</a></li><li><a class="nounderline abstract_t">Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 1998; 159:950.</a></li><li><a class="nounderline abstract_t">Wenske S, Quarrier S, Katz AE. Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre. Eur Urol 2013; 64:1.</a></li><li><a class="nounderline abstract_t">Pisters LL, Rewcastle JC, Donnelly BJ, et al. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008; 180:559.</a></li><li><a class="nounderline abstract_t">Williams AK, Martínez CH, Lu C, et al. Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer. Eur Urol 2011; 60:405.</a></li><li><a class="nounderline abstract_t">Siddiqui KM, Billia M, Al-Zahrani A, et al. Long-Term Oncologic Outcomes of Salvage Cryoablation for Radio-Recurrent Prostate Cancer. J Urol 2016; 196:1105.</a></li><li><a class="nounderline abstract_t">Perrotte P, Litwin MS, McGuire EJ, et al. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 1999; 162:398.</a></li><li><a class="nounderline abstract_t">Robinson JW, Donnelly BJ, Coupland K, et al. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urol Oncol 2006; 24:472.</a></li><li><a class="nounderline abstract_t">Pisters LL, Leibovici D, Blute M, et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009; 182:517.</a></li><li><a class="nounderline abstract_t">Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008; 180:1993.</a></li><li><a class="nounderline abstract_t">Ramey SJ, Marshall DT. Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol 2013; 31:1339.</a></li><li><a class="nounderline abstract_t">Aaronson DS, Yamasaki I, Gottschalk A, et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009; 104:600.</a></li><li><a class="nounderline abstract_t">Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 77:1338.</a></li><li><a class="nounderline abstract_t">Nguyen PL, Chen MH, D'Amico AV, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007; 110:1485.</a></li><li><a class="nounderline abstract_t">Lee HK, Adams MT, Motta J. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Brachytherapy 2008; 7:17.</a></li><li><a class="nounderline abstract_t">Smith WH, Cesaretti J, Chin CP, et al. Salvage low dose rate brachytherapy for prostate cancer recurrence following definitive external beam radiation therapy. Radiother Oncol 2021; 155:42.</a></li><li><a class="nounderline abstract_t">Crook J, Rodgers JP, Pisansky TM, et al. Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526). Int J Radiat Oncol Biol Phys 2022; 112:1115.</a></li><li><a class="nounderline abstract_t">Chen CP, Weinberg V, Shinohara K, et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 2013; 86:324.</a></li><li><a class="nounderline abstract_t">van Son MJ, Peters M, Moerland MA, et al. MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients. Int J Radiat Oncol Biol Phys 2020; 107:126.</a></li><li><a class="nounderline abstract_t">Chitmanee P, Tsang Y, Tharmalingam H, et al. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer. Clin Oncol (R Coll Radiol) 2020; 32:259.</a></li><li><a class="nounderline abstract_t">Uchida T, Shoji S, Nakano M, et al. High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. BJU Int 2011; 107:378.</a></li><li><a class="nounderline abstract_t">Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31:1119.</a></li><li><a class="nounderline abstract_t">Autran-Gomez AM, Scarpa RM, Chin J. High-intensity focused ultrasound and cryotherapy as salvage treatment in local radio-recurrent prostate cancer. Urol Int 2012; 89:373.</a></li></ol></div><div id="topicVersionRevision">Topic 6932 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16798415" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17694553" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31718822" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508816" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9380819" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681527" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10654899" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853796" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33309278" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22280856" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000849" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420229" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430278" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Current status of salvage robot-assisted laparoscopic prostatectomy for radiorecurrent prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23721958" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20478594" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impact of prior prostate radiation on complications after radical prostatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7526002" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1873780" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The role of radical surgery in the management of radiation recurrent and large volume prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7543608" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15538239" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15758726" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9610593" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15890586" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16278473" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16140090" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9474190" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22840351" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Salvage cryosurgery of the prostate for failure after primary radiotherapy or cryosurgery: long-term clinical, functional, and oncologic outcomes in a large cohort at a tertiary referral centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18554664" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Salvage prostate cryoablation: initial results from the cryo on-line data registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185115" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27157372" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-Term Oncologic Outcomes of Salvage Cryoablation for Radio-Recurrent Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411046" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Quality of life after salvage cryotherapy: the impact of treatment parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17138127" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19524984" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18817934" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Best practice statement on cryosurgery for the treatment of localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23053208" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Re-irradiation for salvage of prostate cancer failures after primary radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19245439" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20138442" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17701957" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18201939" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33075391" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Salvage low dose rate brachytherapy for prostate cancer recurrence following definitive external beam radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34740768" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23474112" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32006609" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31708350" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21265984" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32593798" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22797110" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : High-intensity focused ultrasound and cryotherapy as salvage treatment in local radio-recurrent prostate cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
